Completed PHASE2 INTERVENTIONAL 1-arm NCT02014454

Safety and Efficacy of Propranolol Eye Drops in Treating Retinopathy of Premature (DROP-PROP)

Safety and Efficacy of Propranolol Eye Drops in Newborns With Retinopathy of Premature (DROP-PROP)

Sponsor: Meyer Children's Hospital IRCCS

Updated 6 times since 2017 Last updated: Jul 6, 2015 Started: Nov 30, 2013 Primary completion: Aug 31, 2014 Completion: Aug 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02014454, this PHASE2 trial focuses on Retinopathy of Prematurity and remains completed. Sponsored by Meyer Children's Hospital IRCCS, it has been updated 6 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Dec 2024 — Present [monthly]

Completed PHASE2
Sep 2024 — Dec 2024 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Nov 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Meyer Children's Hospital IRCCS

Data source: Meyer Children's Hospital IRCCS

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Florence, Italy
• Milan, Italy